stockrow
Monday 9 November 2026
Export ALXO’s income statement to Excel — free account
ALX Oncology Holdings Inc.
ALXO- EPS
- +73.5%
- Free cash flow
- +31.7%
- Total debt
- −3.34%
Quarter to June 2026, against a year earlier
1.16
0.01
+0.87%
Follow ALXO
Alert me
ALX Oncology Holdings Inc. (ALXO) EV/Sales
As of 6 November 2026, ALX Oncology Holdings Inc. (ALXO) trades at a EV/Sales of 14.0×. Over the past ten years it has ranged from −34.2× (March 2025) to 1,169× (September 2021); the current reading is higher than 34% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 478× | 71,560.08% |
| FY2019 | 0.7× | 0.00% |
| FY2018 | 0.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 478× | 71,560.08% |
| Jun 2020 | 0.7× | 0.00% |
| Mar 2020 | 0.7× | 0.00% |
| Sep 2019 | 0.7× | 0.00% |
| 1 more quarters | Free account |
Against its own ten years
Low −34.2×
High 1,169×
Ten-year median
47.3×
Current reading's percentile
15
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.1× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.1× |
| ALXO ALX Oncology Holdings Inc. | 14.0× |
| ORMP Oramed Pharmaceuticals Inc. compare | 26.8× |
| INO Inovio Pharmaceuticals, Inc. compare | 206× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)